news

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

06.18.2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06.10.2024

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

06.06.2024

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

06.04.2024

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

06.03.2024

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

05.29.2024

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

05.24.2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05.15.2024

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

05.14.2024

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

05.13.2024

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

05.02.2024

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

05.02.2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04.10.2024

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

04.07.2024

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03.20.2024

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

03.05.2024

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

03.04.2024

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

03.04.2024

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

02.22.2024

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

02.07.2024

news

Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter, and Facebook to keep up with all of the latest news.

news archive

icon icon